Therapeutic antibodies protected nerve–muscle connections in a mouse model of Lou Gehrig's disease

February 20, 2018 by Greg Williams, NYU Langone Health
An MRI with increased signal in the posterior part of the internal capsule which can be tracked to the motor cortex consistent with the diagnosis of ALS. Credit: Frank Gaillard/Wikipedia

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, causes lethal respiratory paralysis within several years of diagnosis. There are no effective treatments to slow or halt this devastating disease. Mouse models of ALS reproduce the hallmarks of the disease, including a loss of nerve-muscle connections, called neuromuscular synapses, and a subsequent loss of nerve cells that connect to muscle, called motor neurons.

Now a new study led by NYU School of Medicine researchers identifies a novel treatment strategy that preserved neuromuscular in a mouse model of aggressive ALS. Published February 20 in the journal eLife, the study found that the loss of such synapses was reduced in ALS mice injected with that stimulate a molecule in muscle which keeps nerves attached to the muscle.

By boosting the action of a protein called MuSK, the new approach slowed the loss of neuromuscular synapses, temporarily extended survival of , and extended the lifespan of ALS mice.

"Our findings reveal a new therapeutic strategy for ALS that protects a pathway essential for keeping nerves and muscles connected," says Steven Burden, PhD, a professor in the Skirball Institute of Biomolecular Medicine, and in the Department of Neuroscience and Physiology, at NYU School of Medicine.

"There are few treatments for ALS, and the two FDA-approved drugs extend survival for only a few months in a subset of patients," says Burden. "We believe that our approach, mostly likely in combination with other drugs, may extend quality of life during the early phases of this ."

Study Details

The results are based on the ability of neurons to pass messages to one another or to other targets, including skeletal muscle, at specialized junctions. Motor neurons connect to skeletal muscle at neuromuscular synapses, and the dismantling of these synapses is an early sign of disease in ALS. Although this dismantling is known to be a primary cause of ALS paralysis, most experimental treatments have sought to instead stop the death of motor neurons, which happens later in the disease course, researchers say.

The new approach centers on MuSK, a receptor tyrosine kinase on the muscle cell surface. Once stimulated by a signal provided by the , MuSK provides instructions for building the neuromuscular synapse, including the attachment of motor nerve endings to muscle.

To test whether increasing attachment between nerve and muscle might keep synapses connected when they would otherwise be dismantled in ALS mice, the researchers used an antibody that stimulates MuSK to boost signaling from muscle to nerve. A single dose of a MuSK-stimulatory antibody, introduced into ALS mice after disease onset, increased the number of fully innervated neuromuscular synapses 2.6-fold.

Chronic dosing with the stimulatory antibody led to a sustained increase in the number of neuromuscular synapses for two months, and improved function of diaphragm , which is critical for breathing. Untreated ALS mice survive for about five months, and the MuSK-stimulatory antibody prolonged their survival by about week.

"The therapeutic strategy described here targets a disease mechanism, namely the loss of neuromuscular synapses, which is common to familial and sporadic forms of ALS; and is based on a therapeutic antibody format with considerable clinical precedence," says Burden. "Although the MuSK agonist antibody cannot override the many pathological pathways that occur in motor neurons and in non-neuronal cells, therapeutic interventions that preserve neuromuscular synapses have the potential to improve the quality of life for a majority of ALS patients."

Explore further: Spinal muscular atrophy: New clues to cause and treatment

More information: Sarah Cantor et al. Preserving neuromuscular synapses in ALS by stimulating MuSK with a therapeutic agonist antibody, eLife (2018). DOI: 10.7554/eLife.34375

Related Stories

Spinal muscular atrophy: New clues to cause and treatment

May 15, 2017
Spinal muscular atrophy (SMA), a neurodegenerative disease that causes progressive muscle wasting and paralysis, may be partly due to abnormalities in the synapses that connect sensory neurons and motor neurons, according ...

When nerve meets muscle, biglycan seals the deal

February 14, 2012
A protein that has shown early promise in preventing the loss of muscle function in mouse models of Duchenne muscular dystrophy, has been found in a new study to be a key player in the process of joining nerves to muscles.

Resveratrol preserves neuromuscular synapses, muscle fibers in aging mice

March 7, 2017
Scientists have discovered that resveratrol, a compound in the skin of red grapes and red wine, and metformin, a drug often prescribed to fight type 2 diabetes, have many of the neuroprotective benefits of a low-calorie diet ...

Differences in how ALS affects eye and limb muscles act as clue

June 2, 2016
In an effort to better understand what happens during Amyotrophic Lateral Sclerosis (ALS), researchers at Umeå University in Sweden have compared the impact of ALS on the eye and limb muscles. They have focused on specific ...

Scientists put some muscle behind their research

May 6, 2016
Michigan State University researchers used an old-fashioned neurobiology technique to explore new avenues for treatments to reverse a late-onset neurodegenerative disease that robs men of the capacity to walk, run, chew and ...

Strong communication between brain and muscle requires both having the protein LRP4

July 11, 2012
Communication between the brain and muscle must be strong for us to eat, breathe or walk. Now scientists have found that a protein known to be on the surface of muscle cells must be present in both tissues to ensure the conversation ...

Recommended for you

Wiring diagram of the brain provides a clearer picture of brain scan data

December 14, 2018
Already affecting more than five million Americans older than 65, Alzheimer's disease is on the rise and expected to impact more than 13 million people by 2050. Over the last three decades, researchers have relied on neuroimaging—brain ...

Scientists identify method to study resilience to pain

December 14, 2018
Scientists at the Yale School of Medicine and Veterans Affairs Connecticut Healthcare System have successfully demonstrated that it is possible to pinpoint genes that contribute to inter-individual differences in pain.

Parents' brain activity 'echoes' their infant's brain activity when they play together

December 13, 2018
When infants are playing with objects, their early attempts to pay attention to things are accompanied by bursts of high-frequency activity in their brain. But what happens when parents play together with them? New research, ...

In the developing brain, scientists find roots of neuropsychiatric diseases

December 13, 2018
The most comprehensive genomic analysis of the human brain ever undertaken has revealed new insights into the changes it undergoes through development, how it varies among individuals, and the roots of neuropsychiatric illnesses ...

Researchers find the cause of and cure for brain injury associated with gut condition

December 13, 2018
Using a mouse model of necrotizing enterocolitis (NEC)—a potentially fatal condition that causes a premature infant's gut to suddenly die—researchers at Johns Hopkins say they have uncovered the molecular causes of the ...

Researchers discover abundant source for neuronal cells

December 13, 2018
USC researchers seeking a way to study genetic activity associated with psychiatric disorders have discovered an abundant source of human cells—the nose.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.